Faculty convened at an OncLive Scientific Interchange and Workshop to weigh how new regimens should reshape sequencing in prostate cancer.
Commentary|Articles|April 24, 2025
Oncology Experts Preview Top Abstracts From AUA 2025
Author(s)Caroline Seymour
Fact checked by: Chris Ryan
Experts highlight the top presentations to watch for at the 2025 AUA Annual Meeting.
Advertisement
Advertisement
Ahead of the
Related to this article
Focal therapy for prostate cancer has evolved over 2 decades, with advances in imaging, patient selection, treatment modalities, and clinical trials.
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.
The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.
Advertisement
Advertisement